Nf levels have been used as biomarkers in many NMDs (e.g., dysimmune neuropathies and CMTs, SMA and ALS) to establish axonal damage and degeneration, and neuronal loss. This evidence concerns the gene NFASC and amyotrophic lateral sclerosis.